Aprea Therapeutics, Inc. (APRE)
0.8052
+0.16
(+25.75%)
USD |
NASDAQ |
Aug 24, 16:00
0.802
0.00 (0.00%)
After-Hours: 06:41
Aprea Therapeutics Debt to Equity Ratio : 0.00 for June 30, 2026
Debt to Equity Ratio Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| June 30, 2026 | 0.00 |
| March 31, 2026 | 0.00 |
| December 31, 2025 | 0.00 |
| September 30, 2025 | 0.00 |
| June 30, 2025 | 0.00 |
| March 31, 2025 | 0.00 |
| December 31, 2024 | 0.00 |
| September 30, 2024 | 0.00 |
| June 30, 2024 | 0.00 |
| March 31, 2024 | 0.00 |
| December 31, 2023 | 0.00 |
| September 30, 2023 | 0.00 |
| June 30, 2023 | 0.00 |
| March 31, 2023 | 0.00 |
| Date | Value |
|---|---|
| December 31, 2022 | 0.00 |
| September 30, 2022 | 0.0042 |
| June 30, 2022 | 0.0057 |
| March 31, 2022 | 0.0057 |
| December 31, 2021 | 0.0038 |
| September 30, 2021 | 0.0048 |
| June 30, 2021 | 0.0033 |
| March 31, 2021 | 0.0038 |
| December 31, 2020 | 0.0043 |
| September 30, 2020 | 0.0042 |
| June 30, 2020 | 0.0043 |
| March 31, 2020 | 0.0041 |
| December 31, 2019 | 0.0044 |
| September 30, 2019 | 0.0123 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| Zymeworks, Inc. | 3.343 |
| Rhythm Pharmaceuticals, Inc. | 0.5052 |
| Onconetix, Inc. | 0.0139 |
| ACADIA Pharmaceuticals, Inc. | 0.0565 |
| Alnylam Pharmaceuticals, Inc. | 2.206 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 42.29M |
| Total Liabilities (Quarterly) | 3.092M |
| Shareholders Equity (Quarterly) | 39.20M |
| Current Ratio | 13.55 |